Objective-Obesity and hypertension are comorbid in epidemic proportion, yet their biological connection is largely a mystery. The peptide chemerin is a candidate for connecting fat deposits around the blood vessel (perivascular adipose tissue) to arterial contraction. We presently tested the hypothesis that chemerin is expressed in perivascular adipose tissue and is vasoactive, supporting the existence of a chemerin axis in the vasculature. Approach and Results-Real-time polymerase chain reaction, immunohistochemistry, and Western analyses supported the synthesis and expression of chemerin in perivascular adipose tissue, whereas the primary chemerin receptor ChemR23 was expressed both in the tunica media and endothelial layer. The ChemR23 agonist chemerin-9 caused receptor, concentration-dependent contraction in the isolated rat thoracic aorta, superior mesenteric artery, and mesenteric resistance artery, and contraction was significantly amplified (more than 100%) when nitric oxide synthase was inhibited and the endothelial cell mechanically removed or tone was placed on the arteries. The novel ChemR23 antagonist CCX832 inhibited phenylephrine-induced and prostaglandin F2α-induced contraction (+perivascular adipose tissue), suggesting that endogenous chemerin contributes to contraction. Arteries from animals with dysfunctional endothelium (obese or hypertensive) demonstrated a pronounced contraction to chemerin-9. Finally, mesenteric arteries from obese humans demonstrate amplified contraction to chemerin-9. also play a role in obesity. Additionally, chemerin regulates adipocyte differentiation [18] [19] [20] and production of several proinflammatory cytokines. We hypothesized that a chemerin axis exists in blood vessels. We propose that chemerin and the primary receptor for chemerin, ChemR23, are present and mediate contraction in the vasculature.
T hree classic layers, namely intimal, medial, and adventitial, form the blood vessel as we know it. With the report by Soltis and Cassis 1 in 1991, the perivascular adipose tissue (PVAT) has earned its position as the fourth layer, being called the tunica adiposa. 2 The power of this tissue comes from its ability to synthesize and secrete a multitude of substances that include both vasoconstrictors and vasodilators that can act in a paracrine manner on the blood vessel. 3, 4 PVAT is in the unique position of enabling coordination of the inner compartment of the circulatory system to communicate with the external environment it supports. Most vessels, save the cerebral blood vessels and special vessels such as the tail artery, possess some amount and type of PVAT, varying from mostly brown fat (thoracic aorta) to mixed brown and white fat (mesenteric vessels). PVAT is found in healthy animals, suggesting it performs a physiological function. Dozens of vasoactive substances are released from PVAT, with a majority of substances reducing arterial contraction. 3, 4 Obesity is a situation in which fat is pathologically deposited in the body because of an imbalance of energy intake and expenditure. There is no question that increased visceral body fat (as opposed to subcutaneous body fat) is associated with higher risks of every virtual cardiovascular disease, including hypertension. 5, 6 A low-grade inflammation is described as being part of obesity, 7 and obesity is considered a significant risk factor for developing hypertension. We discovered that an adipokine previously believed to be found only in visceral fat stores and inflammatory cells is also produced by PVAT. Chemerin (tazarotene-induced gene 2) is a peptide secreted as prochemerin from visceral fat and the liver. [8] [9] [10] Originally located in human inflammatory cells, 11 its secretion is attributed to the fat cell itself. 12 Chemerin is described as a biomarker for adiposity because circulating chemerin levels associate strongly with body mass index 13 and is increased in nascent metabolic syndrome, 14 and chemerin levels are reduced with weight and fat loss. 15, 16 Importantly, genetic knockout of the primary receptor for chemerin, ChemR23 (also known as chemokine like receptor 1), is associated with reduced adiposity and body mass. 16 Best known for stimulating movement of dendritic cells and leukocytes, chemerin activates ChemR23, 17 ,18 a G protein-linked receptor, on monocytes and macrophages to elicit recruitment and stimulate an inflammation that could also play a role in obesity. Additionally, chemerin regulates adipocyte differentiation [18] [19] [20] and production of several proinflammatory cytokines. We hypothesized that a chemerin axis exists in blood vessels. We propose that chemerin and the primary receptor for chemerin, ChemR23, are present and mediate contraction in the vasculature.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Arterial Chemerin Axis
Isolated rat arteries express chemerin protein in the PVAT ( Figure 1A ). Real-time polymerase chain reaction supports the expression of chemerin (RARRES2) mRNA in the rat thoracic aortic PVAT (whole PVAT; threshold cycle [C T ] =22.78±0.35; β2-microglobulin as control = 19.32±0.27; n=6). Chemerin signal does not wholly derive from resident mast cells because there was negligible CD68 staining in PVAT ( Figure 1B , + control below), and staining for chemerin was, in many places, not punctate. Positive staining was observed within the cytoplasm of the fat cell, outside the rounded lipid droplet. The predominant receptor for chemerin, ChemR23, is expressed in the tunica media and endothelial cell layer ( Figure 1C ) and is observed as 3 dominant bands in homogenates (−PVAT) of the thoracic aorta and superior mesenteric artery cleaned of PVAT ( Figure 1D and 1E). Two bands (at arrows) are consistent with that observed in a JAR (choriocarcinoma) positive control and were 42 kDa (expected size for ChemR23) and ≈84 kDa in size.
In endothelium intact (+E) rat aorta ( Figure 2A ) and rat superior mesenteric artery without PVAT ( Figure 2C , left panel), the ChemR23 agonist chemerin-9 21 caused a small concentration-dependent contraction from baseline. When arteries were contracted with phenylephrine before chemerin-9, chemerin-9 first caused a modest relaxation that converted to an amplified contraction. This was readily visualized in tissues with no PVAT ( Figure 2B and 2C, right panel). Amplification occurred regardless of whether an agonist of G protein-coupled receptors (prostaglandin F2alpha [PGF2alpha] or the adrenergic agonist phenylephrine [PE]) or a depolarizing stimulus (KCl) was used to contract the tissues ( Figure 2D, left) . The L type calcium channel antagonist nifedipine (100 nmol/L) reduced not only agonist tone (KCl in this example; contraction to KCl abolished by nifedipine) but also the amplified contraction to chemerin-9 ( Figure I in the online-only Data Supplement). Removal of nitric oxide synthase activity by using N-ω-nitro-L-arginine (LNNA) and, to a greater extent, removal of the endothelial cell amplified chemerin-9-induced arterial contraction ( Figure 2D , right). Similar PE-induced amplification of chemerin-9 contractions was observed in arteries from diet-induced obese and stroke-prone spontaneously hypertensive rats, when compared with controls ( Figure II anti-inflammatory chemerin, 22 did not stimulate baseline or agonist-enhanced contraction ( Figure III in the online-only Data Supplement). When chemerin-9 was acutely infused into the LNNA-treated rat (0.1 mg/µL at 200 µL/min for 5 minutes), mean arterial blood pressure was not elevated (control =102±3 mm Hg; during infusion =104±4 mm Hg; n=3). This concentration/dose of chemerin-9 was sufficient to stimulate vasoconstriction in the isolated artery.
CCX832 was developed as a ChemR23 antagonist. The Table reports the low nanomolar affinity of CCX832 for ChemR23 receptors of the human, mouse, and rat. CCX832 does not possess appreciable affinity for 2 other chemerin receptors, G protein-receptor 1 and chemokine receptor like 2, as well as a host of related chemokine receptors (Table I in the online-only Data Supplement). CCX823 inhibited chemerin-9-induced calcium mobilization and chemotaxis in multiple cell types. The significant affinity of CCX832 at rat ChemR23 supported our use of CCX832 as a receptor antagonist in isolated tissue bath studies. CCX832 rightward shifted chemerin-9-induced contraction ( Figure 3A ; −log EC 50 [M] vehicle =6.53±0.05; 50 nmol/L =5.60±0.41; 100 nmol/L =5.20±0.06; P<0.05) and reversed chemerin-9-induced contraction, whereas the inactive analog of CCX832, CCX826, did not ( Figure 3B , tracing left, quantitation right). Endogenous chemerin from PVAT supports agonist-induced contraction because CCX832 reduced contraction to low concentrations of α 1 -adrenergic agonist phenylephrine ( Figure 3C , left panel); CCX832 was without effect on phenylephrine-induced contraction in tissues without PVAT. CCX832 also reduced PGF2α-induced contraction in the rat thoracic aorta +PVAT ( Figure 3C , middle panel). By contrast, CCX832 was ineffective in reducing KClinduced contraction in tissues with PVAT ( Figure 3C , right). Thoracic aortae from the global ChemR23 knockout mouse and wild-type mouse were unresponsive to human chemerin-9 ( Figure IVA in the online-only Data Supplement). These same aortae that contracted with half-maximal PE did not contract or relax to chemerin-9 (data not shown, n=4 for wild-type and knockout rats). ChemR23 protein was observed immunohistochemically in mouse thoracic aorta ( Figure IVB in the onlineonly Data Supplement).
Upregulated Chemerin Axis in Hypertension
Chemerin protein was detected in PVAT around the aorta and superior mesenteric artery of both the sham normotensive (left) and deoxycorticosterone acetate (DOCA)-salt hypertensive rat. Chemerin was detected in the cytoplasm of the In the mesentery, CD68-positive cells were visible in the media, adventitia, and strongly observed in mesenteric lymph nodes, especially of the DOCA-salt tissue ( Figure 4C , bottom row). By contrast, CD68 staining was not observed in the thoracic aorta, and lymph nodes were not observed in the fat around the thoracic aorta. Baseline chemerin-9-induced contraction was significantly increased in the aorta and superior mesenteric artery of the DOCA-salt hypertensive rat ( Figure 5A and 5B). The relationship between chemerin-9-induced maximum contraction in rat aorta and superior mesenteric artery from baseline and endothelial function (acetylcholine-induced relaxation [1 µmol/L] in tissues half-maximally contracted to PE) was inverse. Results from 32 different samples from normal Sprague Dawley, Sprague Dawley+LNNA, or endothelium removed, diet-induced obese, sham normotensive, DOCA-salt hypertensive, and stroke-prone spontaneously hypertensive rats are included in Figure 5C . Tissues that relaxed to ACh >20% had a modest contraction to chemerin-9 from baseline. In tissues with <20% relaxation (dashed line), chemerin-9-induced contraction from baseline was significantly increased. The relevance of the chemerin axis to human arterial function is supported by the expression of ChemR23 in the media ( Figure 6A , higher magnification right), chemerin protein expression in PVAT and adipose cell cytoplasm ( Figure   6B ) and the ability of chemerin-9 to stimulate both baseline and agonist amplified contraction in the isolated human small mesenteric artery ( Figure 6C ). Importantly, resistance arteries from the same area of the rat (mesentery) demonstrate baseline constriction and agonist potentiated contraction to chemerin-9 ( Figure 6D ).
Discussion
In the past 2 years, reports from human studies support a positive association of circulating chemerin concentration with both systolic and diastolic blood pressure. 13, 15, [23] [24] [25] [26] [27] [28] [29] [30] Patient populations in these studies include those with obstructive sleep apnea, preeclampsia, nonalcoholic fatty liver disease, obesity, metabolic syndrome, type 2 diabetes mellitus, and type 2 diabetes mellitus with hypertension. In healthy humans, plasma chemerin is estimated to be from 4 to 40 nmol/L. 13, 15 Plasma is, however, just one of the sources of chemerin to be considered in vascular function. Because chemerin is produced within PVAT, it is likely the concentration of chemerin experienced by the vasculature that is significantly higher than that which is circulating. Importantly, the concentrations we use experimentally are in this physiological range. The effects of chemerin are most probably balanced or synergized by a host of other PVAT substances, such as adiponectin, that promote arterial relaxation. 31 A recent report suggests that the chemerin/adiponectin ratio can be used as a predictor of metabolic syndrome. 32 We are beginning to understand the potential impact of chemerin on human health with reports, such as that by Min et al. 33 This study is a multi-institution, worldwide study of gene loci associated with metabolic syndrome, a syndrome defined by a group of risk factors that include a large waistline, high plasma triglycerides, low high-density lipoprotein cholesterol, hypertension, and high fasting blood glucose (http://www.nhlbi.nih. gov/health/health-topics/topics/ms/). The gene for chemerin, RARRES2, was 1 of 2 that was elevated to a positive association with metabolic syndrome. This syndrome presents as a constellation of events that are seemingly unrelated in terms of cause. However, our finding that chemerin, a product of adipose tissue (both visceral and PVAT), stimulates receptordependent contraction links in at least 2 of the risk factors in metabolic syndrome (large waistline and hypertension).
Chemerin
Endogenous sources of chemerin include white fat, the liver, the platelet, and PVAT. Chemerin is initially produced as a 163 amino acid precursor (prochemerin, tazarotene-induced gene 2), and processing of prochemerin by proteases is considered the key regulatory mechanism affecting chemerin concentration. Proteases that activate prochemerin include cathepsin G, elastase, tryptase, plasmin, and carboxypeptidases N and B.
10,34-40 Similarly, inactivation of active chemerin peptides is performed by proteases that include neutrophil proteinase, mast cell chymase, and angiotensin-converting enzyme. 41 The present work describes PVAT as a source of chemerin. The presence, function, and balance of these proteases in PVAT are key for determining the production of chemerin peptides that influence vascular function. This includes both the final concentration of peptides and the specific chemerin protein produced. The first N-terminal 20 amino acids are cleaved Assay format: h indicates human; m, mouse; and r, rat.
by an unknown protease to form prochemerin, chemerin 20 to 163. Proteolytic processing of the C terminus results in the multitude of chemerin peptides that have varied activity in promoting chemotaxis (the only end point consistently measured for chemerin; last number is the amino acid residue): chemerin-158 (low activity), chemerin-157 (high activity), chemerin-156 (high activity), chemerin-155 (inactive), chemerin-154 (inactive), chemerin-152 (unknown). 8, 34 The antibody used in the immunohistochemical experiments shared in this article recognizes all these chemerin peptides, as the antibody is directed toward amino acids 29 to 67. Thus, we do not yet know the chemerin isoforms produced in different vascular beds nor how this might change in disease. However, the inflammogen tumor necrosis factor-α stimulates chemerin production from adipocytes, thereby linking chemerin to inflammation. 42 In cultured endothelial cells, chemerin increases generation of mitochondrial reactive oxygen species, thereby perpetuating a cycle of events that potentially underly disease. 43 These findings place the protein chemerin as a link between obesity and inflammation.
New Role for ChemR23
ChemR23, as supported by data in this article, has to be ascribed the new function of modifying vascular tone. Pieces of the potential chemerin axis in the vasculature have been discovered. ChemR23 expression was observed in cultured endothelial and cultured human venous smooth muscle cells, 44, 45 and an atypical chemerin receptor CCRL2 was found in cultured human and mouse vascular endothelial cells. 46 Chemerin has been detected in epicardial and aortic adipose tissue. 47 Chemerin incubation of isolated vessels for 24 hours increased arterial sensitivity to endothelin-1. 48 However, never before have all the elements of the chemerin axis been identified in noncultured vascular smooth muscle as they are in the present report. Importantly, the finding that ChemR23 serves the function of contractility attributes a new function to this receptor. Loss of endothelial function, as occuring in multiple cardiovascular diseases, potentiates the ability of chemerin to increase arterial tone. This suggests that chemerin interacts at both the level of the endothelial cell and smooth muscle cell, supported by ChemR23 expression in both locations. We have not pursued the mechanism of chemerin-induced relaxation, but this will be important given the equivocal effects of chemerin-9 infusion. One reason for the lack of blood pressure elevation is that chemerin-9, at the dose given, may still exert an effect on the endothelium that would support vasorelaxation. Involvement of chemerin in the cardiovascular system becomes increasingly important with discoveries that chemerin stimulates angiogenesis 49 and might promote atherosclerosis 50, 51 and diabetic nephropathy. 52 There are 2 different components of chemerin contractile function in the vasculature. First, chemerin directly causes contraction in arteries without PVAT. It does this from baseline, but contraction is magnified when tone is applied to the tissue before hand. Amplification of chemerin-induced contraction occurred when an activator of a G protein-coupled receptor (adrenergic, prostaglandin) or non-G protein-coupled receptor was used to establish tone. This suggests that a mechanism that underlies elevation of vascular tone, such as influx of extracellular calcium, is the key to potentiating chemerininduced contraction. The ability of nifedipine to reduce agonist (KCl)-induced contraction and potentiation of chemerin-9-induced contraction supports the necessity of having tone to amplify chemerin-induced contraction. This is a postreceptor mechanism of interaction of chemerin and the other agonists. Because all 3 agonists (PE, PGF, and KCl) depend on activation of the L type calcium channel, we suggest that their similar ability to potentiate chemerin-induced contraction is likely attributable to elevation of intracellular calcium.
Second, chemerin may participate in arterial contraction (+PVAT) initiated by other agonists. This is distinct from agonist-induced potentiation of chemerin-induced contraction and is a prereceptor mechanism of interaction. In this instance, we are not adding chemerin to this experiment exogenously but rather are causing its release as interpreted by the ability of the ChemR23 antagonist, CCX832, to reduce agonist-induced contraction. PE and PGF2α-induced contraction was reduced by CCX832, whereas that of KCl was not. Our data suggest that PE and PGF2α initiate a series of events in PVAT that promotes chemerin release, and this does not occur with KCl. In the future, we hope to understand the physiological stimuli that can release chemerin from PVAT. These initial experiments were important in that they suggest stimuli normally experienced by the vasculature can release and use chemerin in their vasoconstriction.
Two other receptors for chemerin exist. Chemokine receptor like 2 is not thought to mediate biological signals of chemerin but to chaperone the chemerin molecule to ChemR23 for biological effect. 8, 9 G protein-receptor 1 binds chemerin, but its role in mediating biological signals of chemerin is unknown. CCX832 has negligible affinity for both of these receptors, underscoring the importance of ChemR23 as a receptor for chemerin. CCX832 was effective in reducing chemerin-9-induced contraction in all tissues examined. More recently, other agonists of ChemR23 have been identified. The Resolvin E1 family members have been suggested to bind to ChemR23 in transfected CHO cells. 53, 54 The presence of a chemerin axis in the artery opens the door for chemerin and potentially resolvin to have functions within the blood vessel itself. The clinical relevance of this chemerin axis is supported by the qualitatively similar findings in the rat and human arteries. These findings contrast with those observed in the mouse thoracic aorta. The thoracic aorta of the wild-type mouse did not contract to chemerin-9, but ChemR23 was present. One explanation for this outcome is that human chemerin-9 cannot activate the mouse receptor. Human and mouse chemerin-9 differ in the first 2 N-terminal amino acids, 55 and this difference could play a role in reactivity. Another explanation revolves around a dichotomy between mouse and rat contractility that has been observed before in this very tissue. Unlike the rat thoracic aorta, the mouse thoracic aorta does not contract to angiotensin II and endothelin-1 56 ; other groups have observed this in response to endothelin-1 and urotensin. [57] [58] [59] The inability of the mouse thoracic aorta ChemR23, similar to the endothelin receptors, to couple to contraction is one interpretation of these findings. Finally, it will be interesting to determine whether other arteries of the mouse are similarly unresponsive.
Looking Forward
It will be critical to understand the role, in vivo, of chemerin and ChemR23 in the regulation of blood pressure. Initial experiments infusing chemerin-9 suggested that in vivo functions of chemerin will not be straightforward. Chemerin-9 infusion did not elevate blood pressure. However, chemerin peptides have not been designed for use in vivo and seem to be largely ineffective, given their rapid metabolism. 59 We are unable to prevent this metabolism because we do not know those proteases responsible for chemerin-9 degradation. This will necessitate design of available peptides that are resistant to metabolism 55 and investigation of the in vivo properties of CCX832. This finding may also illustrate the dual role played by chemerin. Although not investigated presently, low concentrations of chemerin-9 caused a modest relaxation in the isolated rat thoracic aorta, rat superior mesenteric artery, and rat mesenteric resistance artery. Thus, 2 events may be occurring simultaneously such that blood pressure is ultimately not modified. We also cannot discount the possibility that chemerin-9 exerts central nervous system effects to modify blood pressure because ChemR23 has been identified in the brain. 12 Finally, it is unclear how infusion of chemerin-9 adds to already circulating levels of chemerin and whether this dose was sufficient to initiate a physiological change. Circulating levels of chemerin in the rat models used are not known. All these important issues deserve formal attention.
Conclusions
The present work is timely in that investigating PVAT function is a current focus in understanding arterial function. The intimate apposition of PVAT to the arterial wall makes PVAT perfectly poised to affect the function of the artery and link adiposity to hypertension and other diseases ( Figure 6E ). PVAT is not the only source of chemerin, but PVAT should be recognized as immediately important to arterial function. Chemerin peptides become new members of the vasoactive PVAT factors, adipokines, that may serve as a connector between obesity and a change in arterial tone.
